Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Neurol Sci. 2020 May 23;41(10):2747–2754. doi: 10.1007/s10072-020-04427-0

Table 2.

Characteristics of included studies

First author
and year		 Countr
y		 Stud
y
type		 Treatmen
t duration
(weeks)		 Patients
with		 Total n
of
patient
s in
study		 Daily
saffro
n dose		 Daily
comparato
r dose		 Cognitiv
e tasks
used
Akhondzade h, 2010 (14) Iran RCT 22 Mild/moderate AD 54 30 mg 10 mg (donepezil) ADAS-Cog, CDRS-SB
Akhondzade h, 2010’ (15) Iran RCT 16 Probable AD 46 30 mg 30 mg (placebo) ADAS-Cog, CDRS-SB
Farokhnia, 2014 (16) Iran RCT 48 Moderate / severe AD 68 30 mg 20 mg (memantine) SCIRS, MMSE FAST
Tsolaki, 2016 (18) Greece RCT 48 aMCI 102 N/R N/R MoCA, MMSE
Moazen-Zadeh, 2018 (17) Iran RCT 12 CABG 55 30 mg 30 mg (placebo) WMS-R, MMSE

ADAS-Cog: AD assessment scale-cognitive subscale; CDRS-SB: Clinical Dementia Rating Scale- Sums of Boxes: SCIRS: Severe Cognitive Impairment Rating Scale; FAST: Functional Assessment Staging; CABG: Coronary Artery Bypass Surgery; WMS-R: Wechsler Memory Scale-Revised MMSE: Mini Mental State Examination; aMCI: amnestic Mild Cognitive Impairment; MoCA: Montreal Cognitive Assessment